Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment

Nuclear Medicine Communications

Volumn 28, Issue 4, 2007, Pages 281-287

  Hanyu, Haruo ^a   Hirao, Kentaro ^a   Shimizu, Soichiro ^a   Iwamoto, Toshihiko ^a   Koizumi, Kiyoshi ^b   Abe, Kimihiko ^b  

^a Tokyo Medical University   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Amlodipine; Cerebral blood flow; Cognition; Hypertension; Mild cognitive impairment; Nilvadipine

Indexed keywords

AMLODIPINE; IOFETAMINE I 123; NILVADIPINE;

AGED; ARTICLE; BRAIN BLOOD FLOW; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FRONTAL LOBE; HUMAN; HYPERTENSION; MALE; NEUROPSYCHOLOGICAL TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE; TEMPORAL LOBE; WECHSLER MEMORY SCALE;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BRAIN; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; HUMANS; HYPERTENSION; NIFEDIPINE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 34247566711     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32804c58aa     Document Type: Article

References (41)

1. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. Fifteen-year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141-1145.
2. Birkenhager WH, Forette F, Seux ML, Wang JG, Staessen JA. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 2001; 161:152-156.
3. Forette F, Seux M-L, Staessen JA, Thijs L, Birkenhager WH, Babarskiene M-R, et al. Prevention of dementia in randomized double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352:1347-1351.
4. Forette F, Seux M-L, Staessen JA, Thijs L, Babarskiene M-R, Babeanu S, et al. The prevention of dementia with antihypertensive treatment. New evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162:2046-2052.
5. Takakura S, Satoh Y, Satoh H, Mori J, Kohsaka M. Effects of nilvadipine on regional cerebral blood flow and skin blood flow in anesthesized cats. Arch Int Pharamacodyn Ther 1992; 319:38-48.
6. Ohtsuka M, Ono T, Hiroi J, Esumi K, Kikuchi H, Kumada S. Comaprison of the cardiovascular effect of FR342235, a new dihydropyridine, with other calcium antagonists. J Cardiovasc Pharmacol 1983; 5:1074-1082.
7. Tokuma Y, Fujiwara T, Noguchi H. Absorption, distribution and excretion of nilvadipine, a new dihidropyridine calcium antagonist, in rats and dogs. Xenobiotica 1987; 17:1341-1349.
8. Takakura S, Sogabe K, Satoh H, Mori J, Fujiwara T, Totsuka Z, et al. Nilvadipine as a neuroprotective calcium entry blocker in a rat model of global cerebral ischemia. A comparative study with nicardipine hydrochloride. Neurosci Lett 1992; 141:199-202.
9. Ogasawara K, Noda A, Yasuda S, Kobayashi M, Yukawa H, Ogawa A. Effect of calcium antagonist on cerebral blood flow and oxygen metabolism in patients with hypertension and chronic major cerebral artery occlusion: a positron emission tomography study. Nucl Med Commun 2003; 24:71-76.
10. Shimamoto H, Shimamoto Y. Nilvadipine increases cerebral blood flow in elderly hypertensives: comparison with nifedipine. J Hum Hypertens 1995; 9:271-279.
11. Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, et al. Nilvadipine antagonizes both Aβ vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res 2004; 999:53-61.
12. Highes CP, Berg L, Danzieger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572.
13. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
14. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999; 56:303-308.
15. Sheikh JL, Yesavage JA. Geriatric depression scale (GDS), recent evidence and development of a shorter version. Clin Gerontologist 1986; 5:165-173.
16. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36:1238-1248.
17. Talairach J, Tournoux P. Co-Planar Stereotactic Atlas of the Human Brain. New York: Thieme; 1998.
18. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: Linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994; 35:1528-1537.
19. Mizumura S, Kumita S, Cho K, Ishihara M, Nakajo H, Toba M, et al. Development of quantitative analysis method for stereotactic brain image: Assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med 2003; 17:289-295.
20. Cooper DB, Lacritz LH, Weiner MF, Rosenberg RN, Cullum CM. Category fluency in mild cognitive impairment. Reduced effect of practice in test-retest conditions. Alzheimer Dis Assoc Disord 2004; 18:120-122.
21. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58:1985-1992.
22. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352:2379-2388.
23. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamid therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069-1075.
24. Morich FJ, Bieber F, Lewis JM, Kaiser L, Cutler NR, Escobar JI, et al. Nimodipine in the treatment of probable Alzheimer disease. Results of two multicentre trials. Clin Drug Invest 1996; 11:185-195.
25. Hanon O, Pequignot R, Seux ML, Lenoir H, Bune A, Rigaud AS, et al. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens 2006; 24:2101-2107.
26. 2+ channel blockers attenuate β-amyloid peptide toxicity to cortical neurons in culture. J Neurochem 1994; 62:372-375.
27. Amenta F, Strocchi P, Sabbatini M. Vascular and neuronal hypertensive brain damage: protective effect of treatment with nicardipine. J Hypertens 1996; 14 (suppl 3):S29-S35.
28. Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer disease. Drugs 1997; 53:752-768.
29. Pascale A, Etcheberrigaray R. Calcium alterations in Alzheimer disease: pathophysiology, models and therapeutic opportunities. Pharmacol Res 1999; 39:81-88.
30. Thibault O, Porter NM, Chen K-C, Blalock EM, Kaminker PG, Clodfelter GV, et al. Calcium dysregulation in neuronal aging and Alzheimer disease: history and new directions. Cell Calcium 1998; 24:417-433.
31. Zipfel GJ, Lee J-M, Choi DW. Reducing calcium overload in the ischemic brain. New Engl J Med 1999; 341:1543-1544.
32. Suo Z, Humphrey J, Kundtz A, Sethi F, Placzek A, Crawford F, et al. Soluble Alzheimers β-amyloid constricts the cerebral vasculature in vivo. Neurosci Lett 1998; 257:77-80.
33. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C. Aβ-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 2001; 281:H2417-H2424.
34. Paris D, Town T, Mori T, Parker TA, Humphrey J, Mullan M. Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol Aging 2000; 21:183-197.
35. Yagami T, Ueda K, Asakura K, Kuroda T, Hata S, Sakaeda T, et al. Effects of endothelin B receptor agonists on amyloid β protein (25-35)-induced neuromal cell death. Brain Res 2002; 948:72-81.
36. Mason RP, Leeds PR, Jacob RF, Hough CJ, Zhang K-G, Mason PE, et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 1999; 72:1448-1456.
37. Iwasaki K, Mishima K, Egashira N, Al-khatib IH, Ishibashi D, Irie K, et al. Effect of nilvadipine on the cerebral ischemia-induced impairment of spatial memory and hippocampal apoptosis in rats. J Pharmacol Sci 2003; 93:188-196.
38. Yamamoto M, Suzuki M, Ozawa Y, Uchida S, Yamada S, Kimura R. Effects of calcium channel blockers on impairment of brain function in senescence-accelerated mice. Arch Int Pharmacodyn Ther 1995; 330:125-137.
39. 2+ antagonists on motor activity and the dopaminergic system in aged mice. Neurobiol Aging 2003; 24:315-319.
40. Oyanagui Y, Sato S. Inhibition by nilvadipine of ischemic and carrageenan paw edema as well as superoxide radical production from neutrophils and xanthine oxidase. Arzneimittelforschung 1991; 41:469-474.
41. Oyanagui Y, Horiai H, Ohtsuka M. Effect of nilvadipine in weak acidic medium by 1,1-diphenyl-2-picryl-hydrazyl (DPPH) assay. Arzneimittelforschung 2001; 51:214-220.